A smart devices based secondary prevention program for cerebrovascular disease patients.
atrial fibrillation
cerebrovascular disease
mHealth
prevention
smart devices
stroke
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
02
2023
accepted:
11
05
2023
medline:
19
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Commercially available health devices are gaining momentum and represent a great opportunity for monitoring patients for prolonged periods. This study aimed at testing the feasibility of a smart device-based secondary prevention program in a cohort of patients with cryptogenic stroke. In this proof-of-principle study, patients with non-disabling ischemic stroke and transient ischemic attacks (TIA) in the subacute phase were provided with a smartwatch and smart devices to monitor several parameters - i.e., oxygen saturation, blood pressure, steps a day, heart rate and heart rate variability - for a 4-week period (watch group). This group was compared with a standard-of-care group. Our primary endpoint was the compliance with the use of smart devices that was evaluated as the number of measures performed during the observation period. In total, 161 patients were recruited, 87 in the WATCH group and 74 in the control group. In the WATCH group, more than 90% of patients recorded the ECG at least once a day. In total, 5,335 ECGs were recorded during the study. The median blood pressure value was 132/78 mmHg and the median oxygen saturation value was 97%. From a clinical standpoint, although not statistically significant, nine atrial fibrillation episodes (10.3%) in the WATCH group vs. 3 (4%) in the control group were detected. Our study suggests that prevention programs for cerebrovascular disease may benefit from the implementation of new technologies.
Sections du résumé
Background
UNASSIGNED
Commercially available health devices are gaining momentum and represent a great opportunity for monitoring patients for prolonged periods. This study aimed at testing the feasibility of a smart device-based secondary prevention program in a cohort of patients with cryptogenic stroke.
Methods
UNASSIGNED
In this proof-of-principle study, patients with non-disabling ischemic stroke and transient ischemic attacks (TIA) in the subacute phase were provided with a smartwatch and smart devices to monitor several parameters - i.e., oxygen saturation, blood pressure, steps a day, heart rate and heart rate variability - for a 4-week period (watch group). This group was compared with a standard-of-care group. Our primary endpoint was the compliance with the use of smart devices that was evaluated as the number of measures performed during the observation period.
Results
UNASSIGNED
In total, 161 patients were recruited, 87 in the WATCH group and 74 in the control group. In the WATCH group, more than 90% of patients recorded the ECG at least once a day. In total, 5,335 ECGs were recorded during the study. The median blood pressure value was 132/78 mmHg and the median oxygen saturation value was 97%. From a clinical standpoint, although not statistically significant, nine atrial fibrillation episodes (10.3%) in the WATCH group vs. 3 (4%) in the control group were detected.
Conclusion
UNASSIGNED
Our study suggests that prevention programs for cerebrovascular disease may benefit from the implementation of new technologies.
Identifiants
pubmed: 37333012
doi: 10.3389/fneur.2023.1176744
pmc: PMC10275564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1176744Informations de copyright
Copyright © 2023 Motolese, Capone, Magliozzi, Vico, Iaccarino, Falato, Pilato and Di Lazzaro.
Déclaration de conflit d'intérêts
FC has received travel grants from Biogen, Merck, Teva and Sanofi-Genzyme. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JMIR Form Res. 2019 Oct 17;3(4):e12346
pubmed: 31625951
Indian Heart J. 2022 Mar-Apr;74(2):86-90
pubmed: 35257736
Cardiovasc Digit Health J. 2022 Apr 18;3(3):126-135
pubmed: 35720675
JMIR Mhealth Uhealth. 2019 Jul 19;7(7):e13503
pubmed: 31325288
JAMA. 2021 Jun 1;325(21):2157-2159
pubmed: 34061158
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
Circ Res. 2020 Jun 19;127(1):4-20
pubmed: 32716709
Lancet Neurol. 2020 Jun;19(6):487-488
pubmed: 32470419
Stroke. 2001 Dec 1;32(12):2735-40
pubmed: 11739965
Ann Med. 2003;35(1):36-42
pubmed: 12693611
Lancet Neurol. 2020 Mar;19(3):255-265
pubmed: 31813850
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
J Med Internet Res. 2019 Aug 30;21(8):e14863
pubmed: 31471961
J Am Coll Cardiol. 2020 Jan 28;75(3):333-340
pubmed: 31976872
Stroke. 2010 Apr;41(4):661-6
pubmed: 20185781
N Engl J Med. 2019 May 16;380(20):1906-1917
pubmed: 31091372
Stroke. 2020 Aug;51(8):2435-2444
pubmed: 32646337
IEEE Pulse. 2019 Jan-Feb;10(1):22-25
pubmed: 30872210
N Engl J Med. 2019 Nov 14;381(20):1909-1917
pubmed: 31722151
PLoS One. 2017 Aug 25;12(8):e0183843
pubmed: 28841694
JAMA Cardiol. 2018 May 1;3(5):409-416
pubmed: 29562087
N Engl J Med. 2019 Sep 5;381(10):956-968
pubmed: 31483966
Neurol Sci. 2021 Aug;42(8):3089-3092
pubmed: 34046795
J Eval Clin Pract. 2004 May;10(2):307-12
pubmed: 15189396
Am J Med. 2014 Apr;127(4):e15-6
pubmed: 24655742
JMIR Mhealth Uhealth. 2020 Jul 9;8(7):e17216
pubmed: 32480361
Stroke. 1999 Dec;30(12):2513-6
pubmed: 10582970
Stroke. 2009 Feb;40(2):350-4
pubmed: 19023098
J Neurol Sci. 2019 Jun 15;401:37-42
pubmed: 31005763
Neurology. 1997 Apr;48(4):891-5
pubmed: 9109873
Lancet Neurol. 2018 Dec;17(12):1053-1060
pubmed: 30274772
Stroke. 2003 Aug;34(8):2050-9
pubmed: 12829866
J Stroke. 2022 Sep;24(3):323-334
pubmed: 36221935
Front Neurol. 2020 Oct 07;11:567413
pubmed: 33117262
Stroke. 2020 Sep;51(9):2778-2785
pubmed: 32811383
Oxid Med Cell Longev. 2019 Apr 9;2019:3756750
pubmed: 31093312